The Scientific Program Committee welcomes the submission of abstracts for presentation at MSVirtual2020. A few changes to note:
|Tuesday, February 4, 2020||Abstract Submission opens|
|Wednesday, July 15, 2020||Abstract Submission closes|
|Thursday, July 16, 2020||Late Breaking Abstract Submission opens|
|Wednesday, August 5, 2020||Notification of acceptance or rejection of Regular Abstracts|
|Thursday, August 13, 2020||Late Breaking Abstract Submission closes|
|Monday, August 24, 2020||Notification of acceptance or rejection of Late Breaking Abstracts|
|Tuesday, September 1, 2020||Accepted Regular Abstracts published|
|Friday, September 25, 2020||Accepted Late Breaking Abstracts published|
UPDATE: With other international meetings forced to cancel due to COVID-19, MSVirtual2020 will consider encore abstracts published by a cancelled meeting, as long as the research described has not been formally presented (including as a virtual platform, electronic poster, or other format). We encourage abstracts that contain original material not published at the time of submission.
After you submit your abstract, you will receive a confirmation email with your abstract number. If you do not receive an email confirmation within 24 hours, please contact Online Support at [email protected]. Should you wish to make corrections to an abstract already submitted, you may login to your account via the abstract submission site. Corrections to abstracts can be made up to the abstract submission deadline of Wednesday, July 15, 2020, 23:59 ET for Regular Abstracts and Thursday, August 13, 2020, 23:59 ET for Late Breaking Abstracts.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Interstate Postgraduate Medical Association (IPMA) and ACTRIMS-ECTRIMS. IPMA is accredited by the ACCME to provide continuing medical education (CME) for physicians.
IPMA will designate the Oral Presentations for CME credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The rules governing eligibility of scientific meetings for CME are complicated and continually evolving, in particular the rules related to submissions involving commercial interests (as defined by the ACCME). Please note the following policies concerning abstracts for this meeting, some of which may differ from those of other scientific meetings you may have attended.
Abstracts accepted for Oral Presentations, for which CME credits will be offered, will be designated as such and will be clearly distinguished from non-CME work. For your submission to be included in a plenary session that meets the requirements for AMA Category I credit and adheres to ACCME guidelines, it must meet each of the following criteria:
CME will not be offered for the poster sessions.
Abstracts with authors who are employees of commercial interests, including abstracts solely from commercial interests, will be considered for non-CME Sessions or Poster Sessions.
Abstracts reporting results from collaborative research conducted by both independent investigators (academic, clinician and/or scientist) and investigators who are employees of commercial interests will not be accepted unless the independent investigators are included as authors.
Each abstract will be reviewed by 3-4 external experts. Each reviewer will receive the author(s) name(s) and affiliation along with the abstract. Upon completion of the external review, the final decision of acceptance or rejection will be made by the Congress Planning Committee.
Notification of acceptance or rejection of submitted Regular Abstracts will be sent to the corresponding presenting authors via email by Wednesday, August 5, 2020.
Notification of acceptance or rejection of submitted Late Breaking Abstracts will be sent to the corresponding presenting authors via email by Monday, August 24, 2020.
Full text of Regular Abstracts will be published in the MSVirtual2020 Online Program on Tuesday, September 1, 2020. Full text of Late Breaking Abstracts will be published in the MSVirtual2020 Online Program on Friday, September 25, 2020.
All abstracts will be published in the Multiple Sclerosis Journal following the meeting.
Late Breaking & COVID-19 Abstract submission will open on Thursday, July 16, 2020, and close Thursday, August 13, 2020. The process for submitting Late Breaking Abstracts and COVID-19 Abstracts will be similar to that of Regular Abstracts (see Preparation of Abstracts above).
A select number of Late Breaking Abstracts will be accepted for Oral Presentation during the Late Breaking News Session. The remaining accepted abstracts will be presented as posters.
A select number of COVID-19 Abstracts will be accepted for Oral Presentation during the Special Session: COVID-19. The remaining accepted abstracts will be presented as posters.
During the abstract submission process, a primary keyword (or topic) must be selected that best fits your submission. You will be able to select from the following keywords:
Presenting authors who are students/trainees in the process of obtaining an advanced degree (M.D. or Ph.D.) OR colleagues who have obtained an advanced degree within seven years of the time of registration are considered a Young Investigator. Abstracts from Young Investigators will be considered for an Oral Presentation during the Young Investigator Sessions. Candidates may be students, residents, postdoctoral fellows or junior faculty. If there are extenuating circumstances that may qualify you to be considered a Young Investigator, please contact [email protected]. Final decisions regarding eligibility will be made by the Scientific Program Committee.
If you wish to be considered a Young Investigator, be sure to indicate as such during the abstract submission process. You may be contacted for proof of eligibility if your abstract is selected for an Oral Presentation.
For more information on the Program, Industry Support or any general questions, please contact:
+ 1 608 310 8960
We look forward to connecting soon.Click here to close this window